Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Fabhalta (iptacopan by Year
Fabhalta (iptacopan — paroxysmal nocturnal hemoglobinuria PNH & IgAN/C3G kidney disease) ($M)
Novartis Fabhalta (iptacopan: $505M in FY2025, up 291.5% from a year earlier.
Latest, FY2025
505
Period ended Dec 31, 2025
Change on a year earlier
+291.5%
129 in FY2024
History
3 years
Since FY2023
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Fabhalta 3 | 505 | 129 | 291 | 287”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Fabhalta (iptacopan — paroxysmal nocturnal hemoglobinuria PNH & IgAN/C3G kidney disease) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 505 | +291.5% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 129 | +12,800.0% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 1 | – | Novartis Form 6-K (0001370368-25-000007) ↗ |
Breakdown
What makes up fabhalta (iptacopan
Cite this data
StockData. (2026). Novartis Fabhalta (iptacopan ($M), annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-fabhalta
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.